We used evaluation criteria used to assess technology patents for business development.
 Patent from Dr. Joseph Orgel, which scored well in our assessment. Our goal was to build a business model that would turn Dr. Orgel's patent through the $17 million and 10-year FDA approval process to produce a cure for osteoarthritis.
 Current treatments for osteoarthritis and degenerative bone and cartilage injuries involves either synthetic replacements or bovine source material. Very few technological updates in this field have happened since the early 1980s. 
 Dr. Orgel's collagen patent covers the unbundling of lamprey collagen so it can be rebundled to closely replicate human collagen. This would reduce the extremely high rejection rate found in current implants. 
Screen Shot 2015-03-06 at 4.14.27 PM.png
Screen Shot 2015-03-06 at 4.14.54 PM.png
Screen Shot 2015-03-06 at 4.15.35 PM.png
Screen Shot 2015-03-06 at 4.15.52 PM.png
Screen Shot 2015-03-06 at 4.15.44 PM.png
Screen Shot 2015-03-06 at 4.16.04 PM.png
prev / next